Institutional news

IBEC has become a partner in the Red de Innovación en Tecnologías Médicas y Sanitarias (ITEMAS), an innovation network for medical and health technologies.

ITEMAS, promoted by the Instituto de Salud Carlos III (ISCIII), brings 95 companies and organizations together with 66 medical centres in Spain to collaborate on R+D projects. The partners will also work together on outreach initiatives.

Barcelona is playing host to EIT Health’s very first Summit this week, the highlight of its first year of activities.

IBEC is a core partner in the €2.1 billion Knowledge and Innovation Community (KIC), one of the largest public funded initiatives for health worldwide, with IBEC director Josep Samitier on the Supervisory Board. Barcelona is one of EIT Health’s co-location centers, with the initiative’s Spanish headquarters based at the PCB.

The EIT Health Summit, which is taking place on 23rd-24th November at CosmoCaixa, will bring together up to 350 participants from among the initiative’s partner organisations, education programmes and external stakeholders.

IBEC’s Technology Transfer Unit was in Germany this week to present a new product developed by the IBEC-GENOMICA Joint Unit that carries out analysis to detect Human Papillomavirus (HPV) in a cheap, quick and convenient desktop device.

Head of Technology Transfer Xavier Rubies, as well as representing IBEC as a research centre related to health, joined forces with representatives from GENOMICA S.A.U. to reveal NEDxA, a nano-electronic diagnostic array, at the MEDICA World Forum for Medicine in Düsseldorf on 14th-17th November.

This week a new PhD programme at IBEC funded by the Obra Social “La Caixa”, INPhINIT, opens for applications.

INPhINIT aims to attract international early-stage researchers to the top Spanish research centres in the areas of the life and health sciences, physics, technology, engineering and maths.

In each call, INPhINIT recruits 57 candidates of any nationality, who enjoy a three-year employment contract at the participating research centre of their choice, all of which have been designated by the Spanish ministries as Severo Ochoa, Maria de Maeztu or Carlos III Centres or Units of Excellence.

Last week saw the launch of the ADVANCECAT project, led by the University of Barcelona.

Part of the RIS3CAT community, ADVANCECAT aims to accelerate the development of advanced therapies – medicines based on cell therapy, gene therapy and tissue engineering – in Catalonia from basic research to clinical or industrial transfer.

Formed by 18 organizations in the field of health including two universities, twelve biomedical research institutes – including IBEC – and four companies and private foundations, ADVANCECAT, which is integrated in the NextHealth community and coordinated by Biocat, will bring together public and private sectors for better management of resources in order to get the most out of the Catalan health system.

IBEC has been designated one of just 28 European Centres of Excellence in a new report by the European Commission’s Directorate-General for Research & Innovation.

In the report, IBEC appears alongside 27 other CoEs in Europe in nine H2020 areas: Nanotechnology, Photonics, Advanced Manufacturing, ICT/Cyber Security, Health, Food/Agriculture/Forestry, Energy, Transport, and Climate/Resources. IBEC, which appears under Health, is the only institute in Spain to appear in the table.

Senior researcher Ismael Diez has won an award from the International Society of Electrochemistry (ISE).

The Nanoprobes and Nanoswitches group member is this year’s recipient of the Jaroslav Heyrovsky Prize for Molecular Electrochemistry, which is named after the Czech chemist, inventor and 1959 Nobel Prize winner.

“I’m really happy to have my work recognised by this award, because although I’ve won prizes from the ISE before, this one is for my independent contributions as a senior scientist,” says Ismael, who’s also an assistant professor at the University of Barcelona.

IBEC junior group leader and UB assistant professor Pere Roca-Cusachs is one of ten finalists selected for the American Society for Cell Biology’s Gibco Emerging Leader Prize.

Supported by Thermo Fisher, the international prize recognises emerging leaders in science who are non-tenured faculty holding independent positions in the early phase of their career. Pere has been chosen as a finalist for his research uncovering the biophysical molecular mechanism by which cells sense tissue rigidity and transduce it into downstream signaling.